Stock Market Reviews

RDY (Dr. Reddy's Laboratories Limited) News

Get the latest news, insights, and market updates on RDY (Dr. Reddy's Laboratories Limited). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
  Asian equities traded in the US as American depositary receipts were lower Wednesday morning, declin
  Dec 17, 2025 - $RDY
• Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
  Asian equities traded in the US as American depositary receipts were tracking lower Tuesday morning,
  Dec 16, 2025 - $RDY
• Immutep (IMMP) Scores Win After Announcing Deal With Indian Firm
  We recently published 7 Best ASX Stocks to Buy Right Now. Immutep Limited (NASDAQ:IMMP) is one of the best ASX stocks. Immutep Limited (NASDAQ:IMMP) is a biotechnology company developing therapies for cancer and autoimmune diseases. The firm’s shares underwent notable traction earlier this week after Indian firm Dr. Reddy’s Laboratories Ltd.’s subsidiary entered into an […]
  Dec 15, 2025 - $RDY
• Asian Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading
  Asian equities traded in the US as American depositary receipts started the week little changed Mond
  Dec 15, 2025 - $RDY
• Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat
  Asian equities traded in the US as American depositary receipts were tracking lower Friday morning,
  Dec 12, 2025 - $RDY
• Asian Equities Traded in the US as ADRs Fall in Thursday Trading
  Asian equities traded in the US as American depositary receipts fell Thursday morning with the S&P A
  Dec 11, 2025 - $RDY
• Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
  Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
  Dec 9, 2025 - $RDY
• Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
  HOUSTON, December 09, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company’s ALSTARS Trial of COYA 302 has commenced.
  Dec 9, 2025 - $RDY
• India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug
  Dec 8 (Reuters) - Indian drugmaker Dr Reddy's signed an exclusive licensing pact with Australia's Immutep to develop and distribute the latter's cancer therapy, the companies said on Monday.
  Dec 8, 2025 - $RDY
• Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
  Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE
  Dec 8, 2025 - $RDY